In today’s recent session, 0.58 million shares of the Immunic Inc (NASDAQ:IMUX) have been traded, and its beta is 1.92. Most recently the company’s share price was $1.29, and it changed around $0.12 or 10.26% from the last close, which brings the market valuation of the company to $116.20M. IMUX at last check was trading at a discount to its 52-week high of $2.11, offering almost -63.57% off that amount. The share price’s 52-week low was $0.92, which indicates that the recent value has risen by an impressive 28.68% since then. We note from Immunic Inc’s average daily trading volume that its 10-day average is 0.46 million shares, with the 3-month average coming to 875.77K.
Immunic Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IMUX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Immunic Inc is expected to report earnings per share of -0.24 for the current quarter.
Immunic Inc (NASDAQ:IMUX) trade information
Instantly IMUX has been showing a green trend so far today with a performance of 10.26% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.3500 on recent trading dayincreased the stock’s daily price by 4.44%. The company’s shares are currently up 29.00% year-to-date, but still up 14.16% over the last five days. On the other hand, Immunic Inc (NASDAQ:IMUX) is 7.50% up in the 30-day period. We can see from the shorts that 2.4 million shares have been sold at a short interest cover period of 2.76 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 74.2% from its current value. Analyst projections state that IMUX is forecast to be at a low of $5 and a high of $5.
Immunic Inc (IMUX) estimates and forecasts
Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.12%. Immunic Inc earnings are expected to increase by 54.22% in 2025, but the outlook is positive 30.57% per year for the next five years.
Immunic Inc (NASDAQ:IMUX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.04% of Immunic Inc shares, and 59.43% of them are in the hands of institutional investors. The stock currently has a share float of 60.05%. Immunic Inc stock is held by 81.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 9.15% of the shares, which is about 8.9 million shares worth $9.88 million.
AVIDITY PARTNERS MANAGEMENT LP, with 9.15% or 8.9 million shares worth $9.88 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 2.63 shares worth $3.47 million, making up 2.92% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 1.18 shares worth around $1.55 million, which represents about 1.30% of the total shares outstanding.
